Miami, FL – August 4, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, reports on Glucose Health, Inc. (OTC Pink: GLUC).
An article on Motley Fool addresses that same topic.
It takes you from what diabetes is, to how large the problem is. It then discusses treatment and factors that drive the market.
Diabetes stocks fall into three broad categories: Drug makers, medical-device makers, and companies that market medical supplies for diabetes. The article further breaks down the largest in each respective space.
|Abbott Laboratories (NYSE:ABT)||Drugs||$109 billion|
|AstraZeneca (NYSE: AZN)||Drugs||$93 billion|
|Becton Dickinson and Co. (NYSE: BDX)||Medical supplies||$60 billion|
|DexCom (NASDAQ: DXCM)||Medical devices||$8 billion|
|Eli Lilly and Co. (NYSE: LLY)||Drugs||$85 billion|
|Insulet (NASDAQ: PODD)||Medical devices||$5 billion|
|Johnson & Johnson (NYSE: JNJ)||Drugs, medical devices||$325 billion|
|Lexicon Pharmaceuticals (NASDAQ:LXRX)||Drugs||$1 billion|
|MannKind (NASDAQ: MNKD)||Drugs||$270 million|
|Medtronic (NYSE: MDT)||Medical devices||$117 billion|
|Merck & Co. (NYSE: MRK)||Drugs||$159 billion|
|Novo Nordisk (NYSE:NVO)||Drugs||$116 billion|
|Pfizer (NYSE: PFE)||Drugs||$209 billion|
|Regeneron Pharmaceuticals (NASDAQ: REGN)||Drugs||$32 billion|
|Sanofi (NYSE: SNY)||Drugs||$95 billion|
|Senseonics Holdings (NYSEMKT: SENS)||Medical devices||$447 million|
|Tandem Diabetes Care (NASDAQ: TNDM)||Medical devices||$711 million|
But the article has missed a major growth industry, diabetic nutrition. Abbott Labs, is the market leader in diabetic nutrition with its Glucerna brand. For a pure-play on diabetic nutrition, the below company likely has the most room for growth:
Have a look at Glucose Health, Inc. (OTC Pink: GLUC). Glucose Health manufacturers nutritional beverages for the diabetic-adult nutrition consumer retail category under the registered trademark GLUCODOWN®. GLUCODOWN® is infused with a special form of diabetic fiber demonstrated in more than 20 clinical studies to help maintain healthy blood sugar levels and regular digestive health.
Glucose Health, Inc. (OTC Pink: GLUC) just announced triple-digit sales increases at Amazon (NASDAQ: AMZN) as its diabetic customers increasingly buy GLUCODOWN® during COVID-19. GLUCODOWN® is also sold nationwide in-store at Walmart pharmacies (NYSE: WMT), now the third largest pharmacy retailer after Walgreens and CVS.
What are the sales of this company going to look like when the latest GLUCODOWN® sales numbers from Amazon and Walmart come on the books during Q2 and Q3?
Over the past 12 months, GLUC has seen a range of approximately $.20 – $1.90 per share and with only 12.5 million shares outstanding, GLUC could be the best value in the diabetes space and should be on everybody’s watch list.
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.